P Pharming Group NV
P
Closed
1.1 -2.57
Overview
Share price change
24h
Min
1.096
Max
1.133
Income | -10M -5.1M |
|---|---|
Sales | -36M 71M |
P/E Sector Avg | 55.3 51.415 |
EPS | 0.01 |
Profit margin | -7.196 |
Employees | 407 |
EBITDA | -4.8M -2.1M |
Next Earnings | 30 lip 2026 |
|---|
Market Cap | -227M 781M |
|---|---|
Previous open | 3.67 |
Previous close | 1.1 |
Pharming Group NV Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Pharming Group NV Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
